FMR LLC - 25 Jul 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Jul 2023, 08:42:15 UTC
Prior SEC filing
20 Jul 2023
Next SEC filing
14 Sep 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

Key filing fact

FMR LLC filed Form 4 for Turnstone Biologics Corp. (TSBX) on 27 Jul 2023.

Key facts

  • This page summarizes FMR LLC's Form 4 filing for Turnstone Biologics Corp. (TSBX).
  • 12 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 27 Jul 2023, 08:42.

Change

  • Previous filing in this sequence was filed on 20 Jul 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+91,663
Change %
Price
Shares after
91,663
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F1
TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+106,496
Change %
+116%
Price
Shares after
198,159
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F1
TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+150,809
Change %
+76%
Price
Shares after
348,968
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F1
TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+483,684
Change %
+139%
Price
Shares after
832,652
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Footnotes
F1
TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+296,396
Change %
Price
Shares after
296,396
Date
25 Jul 2023
Ownership
Impresa Fund III Limited Partnership
Footnotes
F1
TSBX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,939
Change %
Price
Shares after
4,939
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Advisors Fund V LP
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSBX transaction Derivative

Series D Preferred Stock

Conversion of derivative security

Transaction value
Shares
-91,663
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
91,663
Exercise price
Footnotes
F1
TSBX transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares
-106,496
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
106,496
Exercise price
Footnotes
F1
TSBX transaction Derivative

Series B-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-150,809
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
150,809
Exercise price
Footnotes
F1
TSBX transaction Derivative

Series B-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-483,684
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Fund V LP
Underlying class
Common Stock
Underlying amount
483,684
Exercise price
Footnotes
F1
TSBX transaction Derivative

Series B-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-296,396
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
Impresa Fund III Limited Partnership
Underlying class
Common Stock
Underlying amount
296,396
Exercise price
Footnotes
F1
TSBX transaction Derivative

Series B-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-4,939
Change %
-100%
Price
Shares after
0
Date
25 Jul 2023
Ownership
F-Prime Capital Partners Healthcare Advisors Fund V LP
Underlying class
Common Stock
Underlying amount
4,939
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .